Open AccessEnhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells
Author(s) -
Rimi Hamam,
Dalia Ali,
Radhakrishnan Vishnubalaji,
Zaid F Alsaaran,
Elna Paul Chalisserry,
Musaad Alfayez,
Abdullah Aldahmash,
Nehad M. Alajez
Publication year - 2017
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.199136
Subject(s) - histone deacetylase , cancer research , colorectal cancer , protein kinase b , acetylation , histone deacetylase inhibitor , cancer cell , histone , medicine , biology , apoptosis , cancer , biochemistry , gene
5-Fluorouracil (5-FU) is widely used in the treatment of patients with colorectal cancer (CRC). However, the efficacy of 5-FU as a single agent is limited, with multiple undesired side effects. Therefore, the aim of the current study was to assess the efficacy of CUDC-907 (a dual inhibitor of histone deacetylase and phosphatidylinositide 3-kinase) in combination with 5-FU against CRC cells.